American Academy of Allergy, Asthma, and Immunology Annual Meeting (AAAAI 2020)

Single-inhaler triple therapy combo improves FEV1 in patients with asthma

Elaine Soliven, 20200608000000

Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), a LAMA/ICS/LABA combination, significantly improves trough FEV₁* in symptomatic patients with inadequately controlled asthma compared with FF/VI only, according to the CAPTAIN** study presented at AAAAI 2020.

Omalizumab improves outcomes in chronic rhinosinusitis with nasal polyps

Elaine Soliven, 20200603000000

Treatment with omalizumab, an anti-IgE monoclonal antibody, significantly improves outcomes in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP), regardless of asthma status, based on a pooled analysis of the POLYP 1 and POLYP 2* studies presented at AAAAI 2020.

Dupilumab reduces pruritus, anxiety, depression in atopic dermatitis

Roshini Claire Anthony, 20200518140002

Post hoc analyses of the LIBERTY AD SOLO 1 & 2* and ADOL** trials demonstrated significant reductions in pruritus, anxiety, and depression with dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis (AD).

High insulin levels, parental stress spell risk of asthma

High insulin levels, parental stress spell risk of childhood asthma

Pearl Toh, 20200514190000

Children with high serum insulin levels and whose parents are under stress are more likely to have asthma symptoms, suggest two studies presented at the AAAAI 2020 Meeting.

Epinephrine use less common in adult- vs childhood-onset peanut allergy

Roshini Claire Anthony, 20200512120002

Adults who develop peanut allergy in adulthood are less likely to receive a physician diagnosis of their allergy or use epinephrine compared with those with childhood-onset peanut allergy, according to a study from the US.

Baricitinib benefits even AD patients with comorbidities

Pearl Toh, 20200508183000

Treatment with baricitinib led to clinically meaningful improvements in itch and skin symptoms in patients with moderate-to-severe atopic dermatitis (AD), even in those with additional comorbid atopic conditions, according to a pooled analysis of two phase III studies released in the AAAAI 2020 Meeting.

Intranasal epinephrine: A potential substitute for injections?

Roshini Claire Anthony, 20200428140002

Three studies initially scheduled for presentation at AAAAI 2020 demonstrated that epinephrine delivered intranasally was more rapidly absorbed and led to greater haemodynamic response compared with epinephrine delivered intramuscularly.

Novel subcutaneous IG formulation shows promise for immunoprophylaxis

Audrey Abella, 20200415100000

The investigational IGSC-C 20%* was noninferior and bioequivalent to, and had a similar safety profile with, IGIV-C 10%** for the treatment of primary humoural immunodeficiency (PI)***, highlighting the former’s potential as immunoglobulin (Ig)G replacement therapy for immune prophylaxis, according to phase III data presented at AAAAI 2020.

Lanadelumab may prevent hereditary angioedema attacks

Audrey Abella, 20200331100000

Interim findings from the HELP/HELP OLE* studies presented at AAAAI 2020 have shown that the monoclonal antibody lanadelumab has the potential to reduce hereditary angioedema (HAE) attack rates.